Open Access

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib

  • Authors:
    • Zelong Yang
    • Jie Zhang
    • Xiaotong Lin
    • Di Wu
    • Guixi Li
    • Chunlian Zhong
    • Lei Fang
    • Peng Jiang
    • Liangyu Yin
    • Leida Zhang
    • Ping Bie
    • Chuan‑Ming Xie
  • View Affiliations

  • Published online on: April 4, 2019     https://doi.org/10.3892/or.2019.7098
  • Pages: 3257-3269
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sorafenib remains the standard care for patients with hepatocellular carcinoma (HCC) even though it has low antitumor efficacy. Protein neddylation is abnormally activated in many types of human cancer. However, whether dysregulation of neddylation is involved in HCC progression and whether targeting neddylation sensitizes HCC cells to sorafenib need to be ascertained. In the present study, it was demonstrated that high expression of neddylation components, neural precursor cell expressed, developmentally downregulated 8 (NEDD8) and NEDD8‑activating enzyme 1 (NAE1), were associated with poor survival of patients with HCC. Inhibition of neddylation by MLN4924, a small‑molecule inhibitor of NAE1, significantly inhibited HCC growth, reduced clonogenic survival, increased apoptosis, and decreased migration capacity. Sorafenib alone exhibited minimal anticancer efficacy. However, a combination of sorafenib with MLN4924 at a low concentration significantly enhanced the inhibition of cell proliferation and migration as well as the induction of apoptosis induced by sorafenib. In vivo HCC xenograft mouse models also showed that MLN4924 increased the antitumor efficacy of sorafenib. Mechanistically, MLN4924 enhanced the antitumor activity of sorafenib in HCC cells via upregulation of cullin‑RING E3 ubiquitin ligase (CRL)/Skp1‑Cullin1‑F box (SCF) E3 ubiquitin ligase substrates p21, p27, Deptor and IκBɑ. Taken together, these findings suggest that combination therapy of MLN4924 with sorafenib appears to present an additive effect with a maximal in the treatment of HCC.

References

1 

Le Grazie M, Biagini MR, Tarocchi M, Polvani S and Galli A: Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol. 9:907–920. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, et al: A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 25:80–89. 2019. View Article : Google Scholar : PubMed/NCBI

3 

Yao S, Zhu Y and Chen L: Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 12:130–146. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li X, Rong G, Zhang Y and Li Z: Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol Res. 135:89–101. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Yuan T, Yan F, Ying M, Cao J, He Q, Zhu H and Yang B: Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy. Front Pharmacol. 9:10802018. View Article : Google Scholar : PubMed/NCBI

6 

Sun CY, Li JY, Chu ZB, Zhang L, Chen L and Hu Y: Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: A meta-analysis. Biosci Rep. 37(pii): BSR201703042017. View Article : Google Scholar : PubMed/NCBI

7 

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, et al: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 372:944–953. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Cui D, Xiong X and Zhao Y: Cullin-RING ligases in regulation of autophagy. Cell Div. 11:82016. View Article : Google Scholar : PubMed/NCBI

9 

Maghames CM, Lobato-Gil S, Perrin A, Trauchessec H, Rodriguez MS, Urbach S, Marin P and Xirodimas DP: NEDDylation promotes nuclear protein aggregation and protects the ubiquitin proteasome system upon proteotoxic stress. Nat Commun. 9:43762018. View Article : Google Scholar : PubMed/NCBI

10 

Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ and Hamid O: A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Invest New Drugs. 34:439–449. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, et al: Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924in patients with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer Res. 22:34–43. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, et al: Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin Cancer Res. 22:847–857. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Tong S, Si Y, Yu H, Zhang L, Xie P and Jiang W: MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma. Sci Rep. 7:55992017. View Article : Google Scholar : PubMed/NCBI

15 

Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A and Danilov AV: The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 20:1576–1589. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Cheng M, Hu S, Wang Z, Pei Y, Fan R, Liu X, Wang L, Zhou J, Zheng S, Zhang T, et al: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation. Oncotarget. 7:35643–35654. 2016.PubMed/NCBI

17 

Lan H, Tang Z, Jin H and Sun Y: Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells. Sci Rep. 6:242182016. View Article : Google Scholar : PubMed/NCBI

18 

Wang Y, Luo Z, Pan Y, Wang W, Zhou X, Jeong LS, Chu Y, Liu J and Jia L: Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. Cancer Biol Ther. 16:420–429. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J, Zhao L, Thomas D, Beer DG and Sun Y: Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest. 124:835–846. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Luo Z, Pan Y, Jeong LS, Liu J and Jia L: Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. Autophagy. 8:1677–1679. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Mathewson N, Toubai T, Kapeles S, Sun Y, Oravecz-Wilson K, Tamaki H, Wang Y, Hou G, Sun Y and Reddy P: Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood. 122:2062–2073. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Lu C, Ning Z, Wang A, Chen D, Liu X, Xia T, Tekcham DS, Wang W, Li T, Liu X, et al: USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma. Cancer Lett. 436:139–148. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H, Schicho R, Fickert P and Haybaeck J: New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 83:56–70. 2017. View Article : Google Scholar : PubMed/NCBI

24 

He G and Karin M: NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res. 21:159–168. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Crowley LC, Christensen ME and Waterhouse NJ: Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc 2016. 2016. View Article : Google Scholar

27 

Xie CM, Chan WY, Yu S, Zhao J and Cheng CHK: Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Wang J, Qiu Z and Wu Y: Ubiquitin regulation: The histone modifying enzyme's story. Cells. 7(pii): E1182018. View Article : Google Scholar : PubMed/NCBI

29 

Gupta I, Singh K, Varshney NK and Khan S: Delineating crosstalk mechanisms of the ubiquitin proteasome system that regulate apoptosis. Front Cell Dev Biol. 6:112018. View Article : Google Scholar : PubMed/NCBI

30 

Zhou H, Xu J, Wang S and Peng J: Role of cantharidin in the activation of IKKα/IκBα/NF-κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines. Mol Med Rep. 17:7672–7682. 2018.PubMed/NCBI

31 

Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT and Younossi ZM: Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine. 96:e59042017. View Article : Google Scholar : PubMed/NCBI

32 

Wrzesinski SH, Taddei TH and Strazzabosco M: Systemic therapy in hepatocellular carcinoma. Clin Liver Dis. 15:423–441, vii-x. 2011. View Article : Google Scholar : PubMed/NCBI

33 

Medavaram S and Zhang Y: Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 7:172018. View Article : Google Scholar : PubMed/NCBI

34 

Liu J, Liu Y, Meng L, Ji B and Yang D: Synergistic antitumor effect of sorafenib in combination with ATM inhibitor in hepatocellular carcinoma cells. Int J Med Sci. 14:523–529. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Shukla SK and Rafiq K: Proteasome biology and therapeutics in cardiac diseases. Transl Res. 205:64–76. 2019. View Article : Google Scholar : PubMed/NCBI

36 

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, et al: Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study. Br J Haematol. 169:534–543. 2015. View Article : Google Scholar : PubMed/NCBI

37 

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, et al: Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 37:87–97. 2019. View Article : Google Scholar : PubMed/NCBI

38 

Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou S, Qin P, Dong Z, Hu T and Chen P: Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. Oncol Lett. 15:2583–2589. 2018.PubMed/NCBI

39 

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, et al: Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 131:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI

40 

Paiva C, Godbersen JC, Berger A, Brown JR and Danilov AV: Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis. 6:e18072015. View Article : Google Scholar : PubMed/NCBI

41 

Wang X, Zhang W, Yan Z, Liang Y, Li L, Yu X, Feng Y, Fu S, Zhang Y, Zhao H, et al: Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells. Oncotarget. 7:38380–38391. 2016.PubMed/NCBI

42 

Oladghaffari M, Shabestani Monfared A, Farajollahi A, Baradaran B, Mohammadi M, Shanehbandi D, Asghari Jafar Abadi M and Pirayesh Islamian J: MLN4924 and 2DG combined treatment enhances the efficiency of radiotherapy in breast cancer cells. Int J Radiat Biol. 93:590–599. 2017. View Article : Google Scholar : PubMed/NCBI

43 

Wang S, Zhu M, Wang Q, Hou Y, Li L, Weng H, Zhao Y, Chen D, Ding H, Guo J and Li M: Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death Dis. 9:10272018. View Article : Google Scholar : PubMed/NCBI

44 

Liu X, Tian S, Liu M, Jian L and Zhao L: Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF-κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling. Int J Mol Med. 38:1250–1256. 2016. View Article : Google Scholar : PubMed/NCBI

45 

Huang Y, Chen G, Wang Y, He R, Du J, Jiao X and Tai Q: Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-κB signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun. 503:1035–1041. 2018. View Article : Google Scholar : PubMed/NCBI

46 

Wu S and Yu L: Targeting cullin-RING ligases for cancer treatment: Rationales, advances and therapeutic implications. Cytotechnology. 68:1–8. 2016. View Article : Google Scholar : PubMed/NCBI

47 

Chen L, Liu T, Tu Y, Rong D and Cao Y: Cul1 promotes melanoma cell proliferation by promoting DEPTOR degradation and enhancing cap-dependent translation. Oncol Rep. 35:1049–1056. 2016. View Article : Google Scholar : PubMed/NCBI

48 

Shi Z, Wu X, Ke Y and Wang L: Hint1 Up-Regulates IκBα by Targeting the β-TrCP subunit of SCF E3 ligase in human hepatocellular carcinoma cells. Dig Dis Sci. 61:785–794. 2016. View Article : Google Scholar : PubMed/NCBI

49 

Jin J, Shen X, Chen L, Bao LW and Zhu LM: TMPRSS4 promotes invasiveness of human gastric cancer cells through activation of NF-κB/MMP-9 signaling. Biomed Pharmacother. 77:30–36. 2016. View Article : Google Scholar : PubMed/NCBI

50 

Lu P, Chen J, Yan L, Yang L, Zhang L, Dai J, Hao Z, Bai T, Xi Y, Li Y, et al: RasGRF2 promotes migration and invasion of colorectal cancer cells by modulating expression of MMP9 through Src/Akt/NF-κB pathway. Cancer Biol Ther. 20:435–443. 2019. View Article : Google Scholar : PubMed/NCBI

51 

Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI

52 

Xu CY, Qin MB, Tan LIN, Liu SQ and Huang JA: NIBP impacts on the expression of E-cadherin, CD44 and vimentin in colon cancer via the NF-κB pathway. Mol Med Rep. 13:5379–5385. 2016. View Article : Google Scholar : PubMed/NCBI

53 

Li H, Zhou W, Li L, Wu J, Liu X, Zhao L, Jia L and Sun Y: Inhibition of neddylation modification sensitizes pancreatic cancer cells to gemcitabine. Neoplasia. 19:509–518. 2017. View Article : Google Scholar : PubMed/NCBI

54 

Zheng W, Luo Z, Zhang J, Min P, Li W, Xu D, Zhang Z, Xiong P, Liang H and Liu J: Neural precursor cell expressed, developmentally downregulated 8-activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis. Mol Med Rep. 15:2795–2801. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C. ... Xie, C. (2019). Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib. Oncology Reports, 41, 3257-3269. https://doi.org/10.3892/or.2019.7098
MLA
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C., Fang, L., Jiang, P., Yin, L., Zhang, L., Bie, P., Xie, C."Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib". Oncology Reports 41.6 (2019): 3257-3269.
Chicago
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C., Fang, L., Jiang, P., Yin, L., Zhang, L., Bie, P., Xie, C."Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib". Oncology Reports 41, no. 6 (2019): 3257-3269. https://doi.org/10.3892/or.2019.7098